JAB1‑STAT3 activation loop is associated with recurrence following 5‑fluorouracil‑based adjuvant chemotherapy in human colorectal cancer

Kugimiya,Naruji; Nishimoto,Arata; Hosoyama,Tohru; Ueno,Koji; Takemoto,Yoshihiro; Harada,Eijiro; Enoki ,Tadahiko; Hamano,Kimikazu

doi:10.3892/ol.2017.6994

JAB1‑STAT3 activation loop is associated with recurrence following 5‑fluorouracil‑based adjuvant chemotherapy in human colorectal cancer

Authors:
- Naruji Kugimiya
- Arata Nishimoto
- Tohru Hosoyama
- Koji Ueno
- Yoshihiro Takemoto
- Eijiro Harada
- Tadahiko Enoki
- Kimikazu Hamano
View Affiliations

Affiliations: Department of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755‑8505, Japan
Published online on: September 18, 2017 https://doi.org/10.3892/ol.2017.6994
Pages: 6203-6209

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Jun activation domain‑binding protein 1 (JAB1) has been shown to have multiple roles in tumorigenesis, including the degradation of tumor suppressor proteins such as p53, Smad7, Runx3 and the cyclin‑dependent kinase inhibitor p27Kip1, and the activation of oncogenic transcription factors, such as c‑Jun and hypoxia‑inducible factor‑1α. In addition, our previous study revealed that JAB1 positively regulates signal transducer and activator of transcription 3 (STAT3) DNA‑binding activity in human colon cancer cells. In turn, the oncogenic transcription factor STAT3 positively regulates JAB1 expression, indicative of a positive feedback loop. Furthermore, high JAB1 expression is associated with a poor prognosis in numerous malignant carcinomas. However, the association between JAB1 expression and prognosis in colorectal cancer remains unclear. The aim of the present study was to elucidate the association between JAB1 and STAT3 expression and recurrence in colorectal cancer. In the present study, it was found that high JAB1 expression in primary colorectal cancer tissues is an independent predictor of recurrence following 5‑fluorouracil (5‑FU)‑based adjuvant chemotherapy in colorectal cancer patients, and that high expression of both JAB1 and STAT3 in primary colorectal cancer tissues is associated with a lower recurrence‑free survival rate following 5‑FU‑based adjuvant chemotherapy compared to high expression of only JAB1 or STAT3. Overall, these results suggest that JAB1 is a novel predictive marker of recurrence following 5‑FU‑based adjuvant chemotherapy in colorectal cancer patients, and that the JAB1‑STAT3 activation loop may be a potential therapeutic target in recurrent colorectal cancer following 5‑FU‑based adjuvant chemotherapy.

View Figures

View References

1	Claret FX, Hibi M, Dhut S, Toda T and Karin M: A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature. 383:453–457. 1996. View Article : Google Scholar : PubMed/NCBI
2	Shackleford TJ and Claret FX: JAB1/CSN5: A new player in cell cycle control and cancer. Cell Div. 5:262010. View Article : Google Scholar : PubMed/NCBI
3	Oh W, Lee EW, Sung YH, Yang MR, Ghim J, Lee HW and Song J: Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2. J Biol Chem. 281:17457–17465. 2006. View Article : Google Scholar : PubMed/NCBI
4	Zhang XC, Chen J, Su CH, Yang HY and Lee MH: Roles for CSN5 in control of p53/MDM2 activities. J Cell Biochem. 103:1219–1230. 2008. View Article : Google Scholar : PubMed/NCBI
5	Kim BC, Lee HJ, Park SH, Lee SR, Karpova TS, McNally JG, Felici A, Lee DK and Kim SJ: JAB1/CSN5, a component of the COP9 signalosome, regulates transforming growth factor beta signaling by binding to Smad7 and promoting its degradation. Mol Cell Biol. 24:2251–2262. 2004. View Article : Google Scholar : PubMed/NCBI
6	Kim JH, Choi JK, Cinghu S, Jang JW, Lee YS, Li YH, Goh YM, Chi XZ, Lee KS, Wee H and Bae SC: JAB1/CSN5 induces the cytoplasmic localization and degradation of RUNX3. J Cell Biochem. 107:557–565. 2009. View Article : Google Scholar : PubMed/NCBI
7	Tomoda K, Kubota Y and Kato J: Degradation of the cyclin-dependentkinase inhibitor p27^Kip1 is instigated by Jab1. Nature. 398:160–165. 1999. View Article : Google Scholar : PubMed/NCBI
8	Tomoda K, Kubota Y, Arata Y, Mori S, Maeda M, Tanaka T, Yoshida M, Yoneda-Kato N and Kato JY: The cytoplasmic shuttling and subsequent degradation of p27^Kip1 mediated by JAB1/CSN5 and the COP9 signalosome complex. J Biol Chem. 277:2302–2310. 2002. View Article : Google Scholar : PubMed/NCBI
9	Bae MK, Ahn MY, Jeong JW, Bae MH, Lee YM, Bae SK, Park JW, Kim KR and Kim KW: Jab1 interacts directly with HIF-1alpha and regulates its stability. J Biol Chem. 277:9–12. 2002. View Article : Google Scholar : PubMed/NCBI
10	Bemis L, Chan DA, Finkielstein CV, Qi L, Sutphin PD, Chen X, Stenmark K, Giaccia AJ and Zundel W: Distinct aerobic and hypoxic mechanisms of HIF-alpha regulation by CSN5. Genes Dev. 18:739–744. 2004. View Article : Google Scholar : PubMed/NCBI
11	Nishimoto A, Kugimiya N, Hosoyama T, Enoki T, Li TS and Hamano K: JAB1 regulates unphosphorylated STAT3 DNA-binding activity through protein-protein interaction in human colon cancer cells. Biochem Biophys Res Commun. 438:513–518. 2013. View Article : Google Scholar : PubMed/NCBI
12	Shackleford TJ, Zhang Q, Tian L, Vu TT, Korapati AL, Baumgartner AM, Le XF, Liao WS and Claret FX: Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells. Breast Cancer Res. 13:R652011. View Article : Google Scholar : PubMed/NCBI
13	Hsu MC, Chang HC and Hung WC: HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells. Endocr Relat Cancer. 14:655–667. 2007. View Article : Google Scholar : PubMed/NCBI
14	Sui L, Dong Y, Watanabe Y, Yamaguchi F, Sugimoto K and Tokuda M: Clinical significance of Skp2 expression, alone and combined with Jab1 and p27 in epithelial ovarian tumors. Oncol Rep. 15:765–771. 2006.PubMed/NCBI
15	Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tai Y and Tokuda M: Jab1 expression is associated with inverse expression of p27 (kip1) and poor prognosis in epithelial ovarian tumors. Clin Cancer Res. 7:4130–4135. 2001.PubMed/NCBI
16	Harada K, Kawashima Y, Yoshida H and Sato M: High expression of Jun activation domain-binding protein 1 (Jab1) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation. Anticancer Res. 26:1615–1619. 2006.PubMed/NCBI
17	Dong Y, Sui L, Watanabe Y, Yamaguchi F, Hatano N and Tokuda M: Prognostic significance of Jab1 expression in laryngeal squamous cell carcinomas. Clin Cancer Res. 11:259–266. 2005.PubMed/NCBI
18	Wang Y, Yu YN, Song S, Li TJ, Xiang JY, Zhang H, Lu MD, Ji F and Hu LQ: JAB1 and phospho-Ser10 p27 expression profile determine human hepatocellular carcinoma prognosis. J Cancer Res Clin Oncol. 140:969–978. 2014. View Article : Google Scholar : PubMed/NCBI
19	He SM, Zhao ZW, Wang Y, Zhao JP, Wang L, Hou F and Gao GD: Potential role of Jun activation domain-binding protein 1 and phosphorylated p27 expression in prognosis of glioma. Brain Tumor Pathol. 29:3–9. 2012. View Article : Google Scholar : PubMed/NCBI
20	Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM and Busund LT: Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas. PLoS One. 7:e470682012. View Article : Google Scholar : PubMed/NCBI
21	Fukumoto A, Ikeda N, Sho M, Tomoda K, Kanehiro H, Hisanaga M, Tsurui Y, Tsutsumi M, Kato JY and Nakajima Y: Prognostic significance of localized p27^Kip1 and potential role of Jab1/CSN5 in pancreatic cancer. Oncol Rep. 11:277–284. 2004.PubMed/NCBI
22	Wang F, Wang Y, Yu X, Yang D, Wang Z, Lu C, Yuan Z, Xiao M and Shen A: Significance of Jab1 expression in human esophageal squamous cell carcinoma. J Clin Gastroenterol. 43:520–526. 2009. View Article : Google Scholar : PubMed/NCBI
23	Osoegawa A, Yoshino I, Kometani T, Yamaguchi M, Kameyama T, Yohena T and Maehara Y: Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features. Cancer. 107:154–161. 2006. View Article : Google Scholar : PubMed/NCBI
24	Wang Y, Fei M, Cheng C, Zhang D, Lu J, He S, Zhao Y, Wang Y and Shen A: Jun activation domain-binding protein 1 negatively regulate p27 kip1 in non-Hodgkin's lymphomas. Cancer Biol Ther. 7:460–467. 2008. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Xu T, Su B, Wang C, Wang S, Huang H, Pan Y, Wang D, Wei W, Claret FX and Yang H: Molecular markers to assess short-term disease local recurrence in nasopharyngeal carcinoma. Oncol Rep. 33:1418–1426. 2015. View Article : Google Scholar : PubMed/NCBI